Advocacy at a Glance STEVEN GROSSMAN 9/29/23 Advocacy at a Glance STEVEN GROSSMAN 9/29/23 Virtual Certainty of a Federal Government Shutdown on October 1 Despite Bipartisan Senate Effort Read More Analysis and Commentary STEVEN GROSSMAN 9/29/23 Analysis and Commentary STEVEN GROSSMAN 9/29/23 More Q&A As the Shutdown Becomes Inevitable Read More Advocacy at a Glance STEVEN GROSSMAN 9/22/23 Advocacy at a Glance STEVEN GROSSMAN 9/22/23 HHS Posts FY 2024 Contingency Staffing Plan, Including FDA Materials Read More Analysis and Commentary STEVEN GROSSMAN 9/22/23 Analysis and Commentary STEVEN GROSSMAN 9/22/23 Shutdown Becomes a Near-Certainty: Your Questions Answered Read More Advocacy at a Glance STEVEN GROSSMAN 9/15/23 Advocacy at a Glance STEVEN GROSSMAN 9/15/23 Prospects for Government Shutdown Increase Without Progress on Continuing Resolution Read More Analysis and Commentary STEVEN GROSSMAN 9/15/23 Analysis and Commentary STEVEN GROSSMAN 9/15/23 Q&A: Shutdowns at FDA Are Complicated Part 2 Read More Analysis and Commentary STEVEN GROSSMAN 9/8/23 Analysis and Commentary STEVEN GROSSMAN 9/8/23 Q&A: Shutdowns at FDA Are Complicated Read More Advocacy at a Glance STEVEN GROSSMAN 9/8/23 Advocacy at a Glance STEVEN GROSSMAN 9/8/23 How Likely Is a Shutdown? Read More Advocacy at a Glance STEVEN GROSSMAN 9/1/23 Advocacy at a Glance STEVEN GROSSMAN 9/1/23 Agriculture/FDA Appropriations: Unclear Picture of September Action Read More Analysis and Commentary STEVEN GROSSMAN 9/1/23 Analysis and Commentary STEVEN GROSSMAN 9/1/23 Product Shortages’ Prominent Place on FDA’s Agenda Read More
Advocacy at a Glance STEVEN GROSSMAN 9/29/23 Advocacy at a Glance STEVEN GROSSMAN 9/29/23 Virtual Certainty of a Federal Government Shutdown on October 1 Despite Bipartisan Senate Effort Read More
Analysis and Commentary STEVEN GROSSMAN 9/29/23 Analysis and Commentary STEVEN GROSSMAN 9/29/23 More Q&A As the Shutdown Becomes Inevitable Read More
Advocacy at a Glance STEVEN GROSSMAN 9/22/23 Advocacy at a Glance STEVEN GROSSMAN 9/22/23 HHS Posts FY 2024 Contingency Staffing Plan, Including FDA Materials Read More
Analysis and Commentary STEVEN GROSSMAN 9/22/23 Analysis and Commentary STEVEN GROSSMAN 9/22/23 Shutdown Becomes a Near-Certainty: Your Questions Answered Read More
Advocacy at a Glance STEVEN GROSSMAN 9/15/23 Advocacy at a Glance STEVEN GROSSMAN 9/15/23 Prospects for Government Shutdown Increase Without Progress on Continuing Resolution Read More
Analysis and Commentary STEVEN GROSSMAN 9/15/23 Analysis and Commentary STEVEN GROSSMAN 9/15/23 Q&A: Shutdowns at FDA Are Complicated Part 2 Read More
Analysis and Commentary STEVEN GROSSMAN 9/8/23 Analysis and Commentary STEVEN GROSSMAN 9/8/23 Q&A: Shutdowns at FDA Are Complicated Read More
Advocacy at a Glance STEVEN GROSSMAN 9/8/23 Advocacy at a Glance STEVEN GROSSMAN 9/8/23 How Likely Is a Shutdown? Read More
Advocacy at a Glance STEVEN GROSSMAN 9/1/23 Advocacy at a Glance STEVEN GROSSMAN 9/1/23 Agriculture/FDA Appropriations: Unclear Picture of September Action Read More
Analysis and Commentary STEVEN GROSSMAN 9/1/23 Analysis and Commentary STEVEN GROSSMAN 9/1/23 Product Shortages’ Prominent Place on FDA’s Agenda Read More
